Non-invasive analysis of cancer genomes using cell-free circulating tumour DNA (ctDNA) is being widely implemented for clinical indications. The sensitivity for detecting the presence of ctDNA and genomic changes in ctDNA is limited by its low concentration compared to cell-free DNA of nontumour origin. We studied the feasibility for enrichment of ctDNA by size selection, in plasma samples collected before and during chemotherapy treatment in 13 patients with recurrent highgrade serous ovarian cancer. We evaluated the effects using targeted and whole genome sequencing. Selecting DNA fragments between 90-150 bp before analysis yielded enrichment of mutated DNA fraction of up to 11-fold. This allowed identification of adverse copy number alterations, including MYC amplification, otherwise not observed. Size selection allows detection of tumour alterations masked by non-tumour DNA in plasma and could help overcome sensitivity limitations of liquid biopsy for applications in early diagnosis, detection of minimal residual disease, and genomic profiling.
Text:
Analysis of circulating tumour DNA (ctDNA) by non-invasive sampling of cell-free DNA from plasma is now becoming an important tool in oncology for molecular stratification, monitoring tumour burden and analysis of genomic evolution during treatment [1] [2] [3] . Analysis of ctDNA is technically challenging, as ctDNA is often present in low concentrations in plasma and is mixed with cell-free DNA (cfDNA) of non-cancerous origin, which is generally present at much higher concentrations. In patients with advanced cancers, the median concentration of ctDNA can reach 10% or more of the total cfDNA, but this fraction is much lower in earlier stage cancer, and ctDNA may rapidly decrease following initiation of systemic treatment or surgery 1,2,4,5 . Various strategies have been proposed to improve the sensitivity of ctDNA analysis 2 . Such methods generally focus on a small subset of the genome, such as hot-spot PCR-based assays or ultra-deep sequencing across gene panels 2, [6] [7] [8] [9] . Recent observations that ctDNA fragments may be shorter than non-tumour cfDNA in plasma has led to suggestions that these differences may be exploited to enrich for the tumour-specific signal in plasma DNA [10] [11] [12] [13] [14] . In-silico analysis of ctDNA size differences has been used to enhance the signal for chromosomal changes 13 . However, physical size selection to filter out non-tumour DNA prior to large-scale genomic sequencing has not been demonstrated. Therefore, we tested the hypothesis that selecting DNA fragments of specific sizes could improve the sensitivity of detecting genomic alterations in cfDNA from plasma of cancer patients, enabling the detection of point mutations and copy number alterations that are previously undetectable 11 .
Previous reports using paired-end sequencing reads revealed that cell-free DNA is mostly distributed around a mode at 167 bp, a length that could correspond to the chromatosome (core histones + linker) 15, 16 . This size distribution pattern is characteristic of a caspase-dependant cleavage, therefore it was hypothesized that apoptosis releases a large fraction of cfDNA into the bloodstream 14, 15, 17 .
Previous studies in non-invasive prenatal testing have explored the potential of size selection for enriching the fetal DNA fraction in maternal plasma with both physical and in-silico methods 14, [18] [19] [20] .
However, this analysis of the size distribution cannot be easily generalised to tumour-derived fragments as the characterisation of ctDNA-specific patterns requires analysing fragment sizes of DNA with tumour-derived alterations 13 . Plasma samples from xenografted animal models have shown ctDNA to be highly fragmented below 167 bp 10 and this distribution with a mode at 145 bp has been then confirmed with PCR, atomic force microscopy and recently with whole-genome sequencing 12, 21 . If the distribution differs between tumour-derived and non-tumour derived fragments, sieving fragments by their size could reduce the (often overwhelming) fraction of nontumour cfDNA and improve the signal to noise ratio in downstream analysis.
We first analysed paired-end reads from shallow whole genome sequencing (sWGS) of plasma DNA from animal models xenografted with a human ovarian cancer cells, and confirmed that the distribution of ctDNA differed in this model from non-tumour cfDNA (Fig. 1a, b) . ctDNA in this model was enriched in the size range between 90 and 150 bp, while non-tumour cfDNA was dominant at sizes greater than 150 bp, and peaked at ~166 bp, similar to previous observations in animal models and in human samples 12, 15, 21, 22 . Based on these observations we used an automated electrophoresis agarose gel selection method to isolate DNA fragments between 90 and 150 bp for downstream analysis. We sequenced size-selected DNA using both sWGS and tagged-amplicon deep sequencing (TAm-Seq 23 ), in 26 samples collected from 13 patients with high-grade serous ovarian cancer (HGSOC), and compared the results to those of the same samples without size selection. For each patient, two plasma samples were collected: one pre-treatment, when levels of ctDNA were generally high, and another several weeks after the start of treatment, when levels of ctDNA were often much lower due to treatment 24 . Analysis of the distribution of fragment lengths after in-vitro size selection and sWGS indicated that 96% of resulting reads were in the selected range (Fig. 1c ). For two of the patients, the distribution of fragment sizes obtained by sWGS without size-selection exhibited a degraded pattern of cfDNA, without a prominent peak at 166 bp or the 10-bp increment peaks, which has been observed previously 12, 13, 15 , and is present in all the other cases in this study (Suppl. Fig. 1 ).
Analysis of somatic copy number aberrations (SCNAs) was carried out with sWGS on all plasma samples before and after size selection of DNA fragments between 90 and 150 bp (Fig. 2a) . One case is exemplified in Fig. 2b and 2c (see further data in Supplementary Fig. 2 ). Without size selection, a small number of SCNAs were detected with sWGS in DNA isolated from plasma collected 3 weeks after initiation of treatment from patient OV04-83 (Fig. 2b) . These included focal amplifications in chromosomes 8p, 14p, 17, and 19q that were observed in this sample at very low levels (Suppl. Table 2 ). Analysis of the same DNA sample following size-selection for short DNA fragments revealed an increase in the level of these detected SCNAs, in addition to multiples other SCNAs that were not observed without size selection (Fig. 2c) . The same pattern of SCNAs and focal amplifications was observed in DNA from plasma collected from the same patient before initiation of the treatment, when the fraction of tumour DNA in the plasma was higher (Suppl. Fig. 2 ).
The relative copy number signals in plasma DNA, across a list of 29 genes frequently mutated in HGSOC, were compared with and without size selection of DNA from plasma samples collected during treatment across the cohort of 13 patients. This showed that a large number of SCNAs that were not observed without size selection, could be detected after size selection for shorter DNA fragments, notably as amplifications in key genes such as NF1, PARP2 and MYC ( Fig. 2d and Suppl. Fig. 3 ). More SCNAs could be detected after size selection in 11/13 patients, and the absolute level of the log2ratio was significantly increased after size selection (t-test, p=7.72.10 -9 ). The 2 patients for whom the SCNA signal did not increase exhibited a degraded pattern of cfDNA, which could explain why the size selection had not enriched for ctDNA ( Fig. 2d and Suppl. Fig. 2 ).
We next assessed the detection of SCNAs and point mutations, in plasma samples of the 13 patients collected at baseline (before treatment initiation) and 3 weeks after initiation of chemotherapy treatments, with and without size selection of the plasma DNA ( Fig. 3a and Suppl. Table 1 ). The data from the baseline samples, where ctDNA levels are generally higher 24 , was used to identify and confirm genomic changes, which were then studied in the samples after initiation of treatment, with generally, lower levels of ctDNA. The amplitudes of the absolute log2ratio for the SCNAs were higher, and the concordance of the alterations detected between the baseline and post-treatment samples were improved, with size selection of the plasma DNA ( Fig. 3b and Suppl. Fig. 3 ).
Using sWGS data, we converted the amplitude of the CNAs into a quantitative metric called t-MAD (trimmed Mean Absolute Deviation from copy-number neutrality, see Methods). Size selection of plasma DNA resulted in a median of 1.5 fold (n=26) increase in the t-MAD score (figure 3c and 3d). However, in the samples collected after the initiation of treatment, when ctDNA content was low, the genome wide enrichment was higher (Fig. 3d) , with a median increase of the t-MAD score of 2.9 fold (range: 0.6 -4.5 fold), except for two samples. For those two samples we observed a decrease in the t-MAD score, and an analysis of the size profile before selection for these samples revealed that the DNA had been heavily fragmented, which could explain why the size selection did not result in enrichment for these cases (Suppl. Fig. 1 ). In this dataset, we did not identify a differential effect of size selection on the recovery of specific alterations, suggesting that there is a global genome enrichment post size selection. Additionally, size selection notably led to an increased detection of deletions (Suppl. Fig. 2 ). Analysis with greater sequencing depth, integration of samples from other cancer types and different stages of the disease would help to extend our observations and expand further our understanding of ctDNA biology and fragmentation.
In order to confirm that enrichment for tumour DNA could be observed irrespective of the sequencing approach, we further analysed the mutant allele fractions in the samples using TaggedAmplicon Sequencing (TAm-Seq). We detected a relative enrichment in the ctDNA fraction in all samples exhibiting a typical pattern of cfDNA fragmentation, with a mode of fragment distribution at 166bp, before size selection (Suppl. Fig. 2 ). The enrichment effect was below 2-fold in samples collected pre-treatment, when the ctDNA fractions were high in plasma (20%-50% allele fractions for TP53 mutations as detected by TAm-Seq) ( Fig. 3e and 3f) . Enrichment of the tumour fraction by size selection was much greater, between 5-fold and 11-fold for most samples, in samples collected approximately 3 weeks after initiation of treatment, when levels of ctDNA (without size selection) were low (ranging from <1% to 5% allele fraction for TP53 mutations as previously detected by TAmSeq) (Fig. 3e) . For 8 of the 26 plasma samples (31%) we noted a decrease in the allele fractions of mutant TP53 following size selection; this may be related to loss of rare mutant fragments during the size selection process, or by limitations of this assay for analysis of very short fragments. Increasing the starting amount of material used for size selection, and optimisation of assays for recovery of short fragment, could overcome such limitations.
Methods such as exome-wide sequencing of plasma DNA at multiple time-points of cancer treatment could be effective for the study of cancer evolution and for identification of possible resistance mechanisms to treatment 3, 25 . However, analysis with broads-spectrum approaches such as whole-exome sequencing or sWGS are most effective when the ctDNA content is greater than approximately 5% 3, 26, 27 . In this study, we found that 4 out of 13 cases (31%) where ctDNA levels <5%
may have made such analysis uninformative, have been "rescued" by size selection that resulted in >5% mutant allele fractions (Fig. 3e ).
These results demonstrate a proof-of-principle that by a simple step of filtering of cfDNA and selection of shorter fragments, it is possible to increase the tumour DNA fraction in plasma cell-free DNA samples. A better understanding of the biology of ctDNA, and their mechanism of release in the circulation, could help select specific fragment ranges depending on their expected origin 28, 29 . For example, necrotic cells may release long mutant fragments 14, 17 , and thus size selection for fragments of hundreds to thousands of bp may be appropriate for certain samples. Alternatively, a size selection of ultra-short fragments might help for enriching a sample for mitochondrial circulating DNA or bacterial DNA, as their DNA is further fragmented below 100bp 13, 30 . Other selection or filtration methods can selectively enrich DNA fragments that are bound to specific molecules for example modified nucleosomes 31 Determining and accounting for inherent size-biases induced by DNA isolation method that are currently employed for recovery of cfDNA in practice will be important to standardise and optimise methods for liquid biopsy, as large fractions of short or long DNA could be lost at this step. In addition, recent reports have highlighted that different methods of library preparation for sequencing may enable more effective recovery of short DNA fragments from plasma samples, which have led to new observations on cfDNA size distributions 28, 30, 32 . Such methods should be further investigated to determine if these could help recover more ctDNA.
The size selection process we demonstrated here is based on inherent characteristics of ctDNA in comparison to cfDNA and does not require alteration of these fragments. The enrichment we observed is therefore compatible with any downstream genomic analysis, from locus-specific to wider genomic sequencing. This work shows that sWGS (and by extension, whole exome sequencing) can be performed on plasma DNA samples with low ctDNA content, and that this can facilitate the characterisation of mutations present in plasma at lower allele fractions and with lower sequencing depth. The compatibility of the cfDNA fragment size selection with wide-scale and sensitive genomic analysis could unlock the potential of liquid biopsies for the diagnosis of cancer at an earlier stage, and for the detection of minimal residual disease.
Methods:
Patients and sample preparation. 13 patients were recruited as part of prospective clinical studies at Addenbrooke's Hospital, Cambridge, UK, approved by the local research ethics committee (REC reference numbers 07/Q0106/63, 08/H0306/61 and 07/Q0106/63). Written informed consent was obtained from all patients and blood samples were collected before and after initiation of treatment with chemotherapeutic agents. DNA was extracted from 2 mL of plasma using the QIAamp circulating nucleic acid kit (Qiagen) according to the manufacturer's instructions.
Size selection. Between 8-10 ng of DNA were loaded into a 3% agarose cassette (HTC3010, Sage Bioscience) and size selection was performed on a PippinHT (Sage Bioscience) according to the manufacturer's protocol.
TAm-Seq. Tagged-Amplicon Sequencing libraries were prepared as previously described 23 , using primers designed to assess single nucleotide variants (SNV) and small indels across selected hotspots and the entire coding regions of TP53. Libraries were sequenced using an HiSeq 4000 (Illumina).
sWGS. Indexed sequencing libraries were prepared using a commercially available kit (ThruPLEXPlasma Seq, Rubicon Genomics). Libraries were pooled in equimolar amounts and sequenced on a HiSeq 4000 (Illumina) generating 150-bp paired-end reads. Sequence data was analysed using an inhouse pipeline that consists of the following; Paired end sequence reads were aligned to the human reference genome (GRCh37) using BWA-mem following the removal of contaminating adapter sequences 33 . PCR and optical duplicates were marked using MarkDuplicates (Picard Tools) feature and these were excluded from downstream analysis along with reads of low mapping quality and supplementary alignments.
SCNA analysis: Copy number analysis was performed in R using a modification of the QDNAseq pipeline 34 , as follow: sequence reads were allocated into equally sized (50 kbp) non-overlapping bins throughout the length of the genome. Read counts in each bin were corrected to account for sequence GC content and mappability, and bins overlapping 'blacklisted' regions (ENCODE project) were excluded from downstream analysis. After median normalisation of the counts, bins were segmented using both Circular Binary Segmentation and Locus-aware Circular Binary Segmentation algorithms, and an averaged log2R value per bin was calculated. The t-MAD score is calculated as the averaged absolute deviation from log2R = 0 after first trimming bin counts greater than 4 standard deviations from the mean count across all genomic regions. MSH2  MSH6  APLF  PAX8  BARD1  FANCD2  MLH1  MECOM  TERT  ID4  MYC  APTX  PTEN  CHEK1  BRCA2  RB1  PARP2  FANCM  RAD51B  PALB2  TP53  NF1  RAD51D  CDK12  BRCA1  RAD51C  CCNE1  ZMYND8  CHEK2 with size selection MSH2  MSH6  APLF  PAX8  BARD1  FANCD2  MLH1  MECOM  TERT  ID4  MYC  APTX  PTEN  CHEK1  BRCA2  RB1  PARP2  FANCM  RAD51B  PALB2  TP53  NF1  RAD51D  CDK12  BRCA1  RAD51C  CCNE1  ZMYND8 determined by t-MAD, varied per sample but was lower for was samples collected at baseline (red circles), which had high initial t-MAD score, compared to samples collected after treatment (blue triangle). e. The mutant allele fraction (MAF) determined by targeted sequencing with size selection (vertical) was higher than without size selection (horizontal) for most samples, including samples collected at baseline (red circles) and after initiation of treatment (blue triangles). The dotted area highlights samples with low MAF (<5%), where methods such as whole-exome sequencing (at sequencing depth of ~100x) would not be effective, where size selection enriched the mutant fraction to >5% and therefore accessible for wide-scale analysis. f. Comparison of the MAF detected by TAm-Seq before treatment and after initiation of treatment, as assessed by targeted sequencing, with size selection (yellow triangles) and without size selection (green circles).
Notes

